Idexx Labs Surges to Top 500 Volume Despite 0.18% Slide as Analysts Back Buy Ratings

On August 19, 2025, Idexx Laboratories (IDXX) closed with a 0.18% decline, trading at a daily volume of $250 million—ranking 392nd among U.S. stocks. Analyst activity focused on the veterinary diagnostics firm as Jefferies' Keith Devas reiterated a Buy rating with a $785 price target, while the broader analyst consensus maintained a Moderate Buy stance at $730, suggesting 11.4% upside from current levels. Recent coverage highlighted Devas' 10.6% average return on IDXX recommendations, though his rank of #6,418 out of 9,981 analysts underscores mixed market confidence in his guidance.

William Blair reaffirmed a Buy rating on August 4, aligning with the sector's cautious optimism. The stock's performance remains tied to veterinary healthcare demand and diagnostic innovation, with analysts emphasizing long-term growth potential despite short-term volatility. Market participants are closely watching execution against revised 2025 revenue forecasts, which have yet to translate into consistent momentum in near-term trading patterns.

A backtested strategy of holding the top 500 volume stocks for one day from 2022 yielded a 0.98% average daily return, accumulating 31.52% over 365 days. This suggests IDXX's inclusion in high-volume trades captured transient momentum but reflected inherent risks in timing volatile market conditions.